Suppression of SARS-CoV-2 nucleocapsid protein dimerization by ISGylation and its counteraction by viral PLpro
Frontiers in Microbiology · 24.10.2024 · 15
DOI: 10.3389/fmicb.2024.1490944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 24.10.2024. Verfasst von Wonjin Bang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Protein modification by the ubiquitin-like protein ISG15 (ISGylation) plays a crucial role in the immunological defense against viral infection. During severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, innate immune signaling proteins are ISGylated, facilitating innate immunity. However, whether SARS-CoV-2 proteins are direct substrates for ISGylation remains unclear. In this study, we investigated whether SARS-CoV-2 proteins undergo ISGylation and whether ISGylation affects viral protein function. Co-transfection ISGylation analysis of SARS-CoV-2 proteins showed that the nucleocapsid (N) protein is ISGylated at several sites. Herc5 promoted N ISGylation and interacted with N, indicating that Herc5 acts as an E3 ligase for N ISGylation. Lys-261 (K261) within the oligomerization domain of N was identified as a potential ISGylation site that is necessary for efficient ISGylation of N. K261 is positioned at the center of the dimer interface in the crystal structure of the C-terminal domain dimer and the ISGylated form of N showed reduced protein dimerization in pull-down analysis. Importantly, a recombinant virus expressing K261R mutant N showed enhanced resistance to interferon-β treatment compared to its parental virus. We also found that viral PLpro removes conjugated ISG15 from N. Our findings demonstrate that ISGylation of SARS-CoV-2 N inhibits protein dimerization, resulting in viral growth more susceptible to type I interferon responses, and that viral PLpro counteracts this ISG15-mediated antiviral activity by removing conjugated ISG15 from N.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
- Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Zitieren
APA
Bang, W., Kim, J., Seo, K., Lee, J., Han, J. H., Park, D., Cho, J. H., Shin, D., Kim, K. H., Song, M. J., & Ahn, J. H. (2024). Suppression of SARS-CoV-2 nucleocapsid protein dimerization by ISGylation and its counteraction by viral PLpro. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1490944
Vancouver
Bang W, Kim J, Seo K, Lee J, Han JH, Park D, et al. Suppression of SARS-CoV-2 nucleocapsid protein dimerization by ISGylation and its counteraction by viral PLpro. Frontiers in Microbiology. 2024;15. doi:10.3389/fmicb.2024.1490944
BibTeX
@article{Bang2024,
author = {Bang, Wonjin and Kim, Jaehyun and Seo, Kanghun and Lee, Jihyun and Han, Ji Ho and Park, Daegyu and Cho, Jae Hwan and Shin, Donghyuk and Kim, Kyun-Hwan and Song, Moon Jung and Ahn, Jin-Hyun},
title = {Suppression of SARS-CoV-2 nucleocapsid protein dimerization by ISGylation and its counteraction by viral PLpro},
journal = {Frontiers in Microbiology},
year = {2024},
volume = {15},
doi = {10.3389/fmicb.2024.1490944}
}
EUVIMED